Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

INDICATIVE ANNOUNCEMENT
FIRST PATIENT ENROLLED IN PHASE I CLINICAL OF FZ-P001 SODIUM FOR INJECTION FOR INTRAOPERATIVE VISUALIZATION OF MALIGNANT LESIONS IN OVARIAN CANCER SURGERY

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the "**Company**") on a voluntary basis.

The first patient in the Phase I clinical trial of FZ-P001 Sodium for Injection (the "**Drug**") for intraoperative visualization of malignant lesions in ovarian cancer surgery (the "**Study**") has recently been successfully enrolled in the Study.

ABOUT THE DRUG

FZ-P001 Sodium for Injection is a class 1 new molecular entity independently developed by the Company as an innovative photosensitizer. Its active ingredient is a small molecular drug conjugate composed of a folate receptor-targeted small molecule conjugated with a cyanine-based photosensitizer which targets malignant tumor tissues overexpressing folate receptor alpha (FRα) and enables fluorescence imaging in the near-infrared spectrum. Among the three major gynaecological malignancies, ovarian cancer has the highest mortality rate and poses a serious threat to women's health[1]. The Company plans to develop intraoperative fluorescence guidance technology using the Drug to indicate residual malignant tumor tissues and margin status, aiming to improve surgical

[1] Source: Chinese Society of Clinical Oncology (CSCO) Ovarian Cancer Diagnosis and Treatment Guidelines 2024

resection outcomes for relevant solid tumors, and provide an innovative solution for precision navigation surgery in tumor surgery with both molecular targeting specificity and multidimensional biological sensing.

RESEARCH AND DEVELOPMENT INFORMATION AND PROGRESS OF THE DRUG

The Study was received the approval for the Phase I clinical trial application in August 2025. The Study aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of the Drug in humans. As at the date on the publication of this announcement, the first patient has been successfully enrolled in the Study.

Due to the high-tech, high-risk and high-value-added characteristics of pharmaceutical products, and the long cycle and numerous stages in the process, there are uncertainties in drug pre-clinical research, clinical trial and commercialization. These many stages make it susceptible to uncertainties and therefore, investors are advised to make cautious decisions and pay careful attention to investment risks. The Company will actively facilitate the above research and development project and fulfill its information disclosure obligations in a timely manner for subsequent progress in strict accordance with relevant regulations.

By order of the Board
Zhao Da Jun
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Zhao Da Jun (Executive Director)
Ms. Xue Yan (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Wang Hong Guang (Independent Non-executive Director)
Mr. Lam Siu Wing (Independent Non-executive Director)
Mr. Xu Pei Long (Independent Non-executive Director)
Ms. Qu Ya Nan (Employee Director)

Shanghai, the PRC

9 April 2026
** For identification purpose only*